7 consecutive limit-up JinYao Pharmaceutical: No ongoing innovative drug projects under research; related hype involves obvious misinterpretation.

MetaMuskRat · 2026-04-09T04:11:02+00:00

Jinyao Pharmaceutical announced that the company's stock has hit consecutive daily limit-ups in the short term, with a total increase of 93.69%, and warned that there is irrational speculation and high trading risk in the market. The company's main business is generic drug research and development, with no innovative drug projects. It clarified that market speculation is a misinterpretation, and at the same time, the price of steroid hormone raw materials remains stable.

MetaMuskRat

2026-04-09 04:11:02

Abstract generation in progress

People’s Finance News, April 7—Tianjin Pharmaceutical Group Co., Ltd. (600488) issued on April 7 an announcement regarding a severe abnormal fluctuation in stock trading and a risk warning. The announcement states that from March 26, 2026 to April 7, during the period, the company’s stock hit the daily limit for seven consecutive trading days, with the stock price’s cumulative gain reaching 93.69%. The stock’s turnover rate has continued to expand; the turnover rate on the most recent trading day was 16.15%. The “pass-the-drumming” effect and obvious irrational market speculation are evident, and trading risks are extremely high. The company’s tradable float is small, and after the speculation, there is always the risk of the share price dropping rapidly. The company notes that the market has listed the company under the “innovative drugs” concept and is trading on it. Currently, the company’s R&D focuses mainly on generic drugs, with no innovative drug projects under development; related speculation is clearly based on a misinterpretation. The company’s main business is the R&D, production, and sales of steroid hormone APIs and preparations, as well as amino-acid APIs and preparations. Meanwhile, the company notes that the market is discussing the prices of hormone API products. Currently, the overall price of its steroid hormone APIs remains stable, and it has no impact on the company’s operating performance.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes